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Abstract
Background: We performed multicenter study to define clinical characteristics of noncutaneous melanomas and to 
establish prognostic factors patients who received curative resection.
Methods: Of the 141 patients who were diagnosed of non-cutaneous melanoma at 4 institutions in Korea between 
June 1992 and May 2005, 129 (91.5%) satisfied the selection criteria.
Results: Of the 129 noncutaneous melanoma patients, 14 patients had ocular melanoma and 115 patients had 
mucosal melanoma. For mucosal melanoma, anorectum was the most common anatomic site (n = 39, 30.2%) which 
was followed by nasal cavity (n = 30, 23.3%), genitourinary (n = 21, 16.3%), oral cavity (n = 14, 10.9%), upper 
gastrointestinal tract (n = 6, 4.7%) and maxillary sinus (n = 5, 3.9%) in the order of frequency. With the median 64.5 
(range 4.3-213.0) months follow-up, the median overall survival were 24.4 months (95% CI 13.2-35.5) for all patients, 
and 34.6 (95% CI 24.5-44.7) months for curatively resected mucosal melanoma patients. Adverse prognostic factors of 
survival for 87 curatively resected mucosal melanoma patients were complete resection (R1 resection margin), and age 
> 50 years. For 14 ocular melanoma, Survival outcome was much better than mucosal melanoma with 73.3% of 2 year 
OS and 51.2 months of median OS (P = .04).
Conclusion: Prognosis differed according to primary sites of noncutaneous melanoma. Based on our study, 
noncutaneous melanoma patients should be treated differently to improve survival outcome.
Background
Melonoma is originated from melanocytes, located in
skin epidermis, eye, and epithelia of the nasal cavity,
oropharynx, anus, and genitourinary tract. Melanoma
comprises about 4.3% of all new cancer diagnosed in
United States according to the National Center for Health
Statistics database report[1]. Compared to the cutaneous
melanoma which consists of majority of disease, noncu-
taneous melanomas are relatively rare, which are com-
prised of ocular and various mucosal sites such as
anorectal, vaginal, nasal, and gastrointestinal tract[2]
According to the National Cancer Data Base (NCDB) in
the United States, the incidence of ocular, and mucosal
melanoma were 5.5% and 1.3%, respectively. Intriguingly,
the reported incidence of mucosal melanoma varies from
0.2% to 10.0% depending on the ethnic and geographic
differences [3-5]. In previous studies comparing mela-
noma patient cohort cohort, age-adjusted incidence of
cutaneous melanoma was highest in non-hispanic whites,
and visceral/cutaneous melanoma ratio was much higher
for black individuals[6,7]. The proportion of mucosal
melanoma seems to be higher in Asian ethnicity when
compared with that in Caucasians [8-10]. Moreover,
Asian groups showed the lower age-adjusted incidence
rate of ocular melanoma compare to caucasian patients
[11,12]. Such variations in ethnicity may reflect distinc-
tive pathophysiology or tumorigenesis for each subtypes
of melanoma.
The differential distribution of genetic alterations in
BRAF,  NRAS  and  KIT  among melanoma subtypes
according to anatomic sites and sun exposure strongly
implicated different molecular pathways involved in tum-
origenesis for each subtype (Antonescu et al, 2007). KIT
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mutations were detected in 21% of mucosal melanomas,
11% of acral melanomas, and 16.7% of melanomas arising
in chronically sun-damaged skin as indicated by the pres-
ence of solar elastosis (Antonescu et al, 2007). In another
recent study, KIT  mutations were identified in 23% of
acral melanomas, 15.6% of mucosal melanomas, 1.7% of
cutaneous melanomas, and none in choroidal melano-
mas[13]. Mucosal melanomas pursued more aggressive
natural course and poorer prognosis than other subsets of
melanomas[14]. Nevertheless, owing to the rarity and
heterogeneity of the disease entity, clinical characteristics
and optimal therapeutic strategies have not been exten-
sively defined yet. Given the distinct genetic aberrations
for mucosal melanoma, there is an urgent need to rede-
fine the clinical features and prognosis of this subtype of
melanoma. Most of the previous reports on mucosal mel-
anomas are focused on head and neck melanomas rather
than melanomas arising from mucosal membrane at vari-
ous anatomic sites[3,14-16]. Hence, we undertook this
multicenter retrospective analysis to define clinical char-
acteristics of mucosal melanomas and to devise a prog-
nostic model which can effectively identify different risk
groups based on initial clinical variables.
Methods
Patients
Between June 1992 and May 2005, a total of 141 patients
were newly diagnosed with noncutaneous melanoma at 4
institutions in Korea. The criteria for case inclusion were
as following: (1) pathologically confirmed diagnosis of
melanoma; (2) complete set of clinical information which
was defined by patient demographics, primary tumor
site, stage, treatment record, and vital status. Of the 141
patients, 129 patients (91.5%) were histologically con-
firmed of noncutaneous melanoma with complete set of
clinical data available for review. All patients' stage was
reclassified using the 2002 American Joint Committee on
Cancer (AJCC) melanoma TMN staging classifica-
tion[17] Mucosal melanomas were defined as tumors
arising from mucous membrane such as head and neck,
female genital tract, anorectum, and urinary tract. Ocular
melanomas were defined as tumors involving the con-
junctiva and uvea (arising in iris, ciliary body, and chor-
oid) in this study. This retrospective study was reviewed
and approved by the Samsung Medical Center institu-
tional review board (Seoul, Korea).
Statistics
The primary end point was overall survival (OS), which
was calculated using Kaplan-Meier method. OS was
defined from the date of surgery to date of death related
to the disease or complication. Survival rates were com-
pared for statistical differences using log-rank test. OS
was assessed with respect to following factors: age, sex,
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, presenting symptom, primary site, tumor
burden, and resection margin. Multivariate analysis was
performed using stepwise Cox proportional hazards
regression modeling. P values less than 0.05 were consid-
ered statistically significant and all P values corresponded
to two-sided significance tests. The latter was performed
by Cox's proportional hazard regression model. Because
of different characteristics between mucosal and ocular
melanoma, we performed analysis separately for those
two distinct subsets of patients.
Results
One-hundred twenty nine patients were included in the
analysis. The clinical characteristics are provided in Table
1. After that, we further analyzed survival outcome for
those who had received curative resection (R0 and R1
resection) as shown in Table 2. The median age was 61
years with a range of 26 to 95 years and male proportion
was 40.3%. The median longest diameter of the primary
tumor was 25 mm with a range from 2 to 135 mm. Non-
cutaneous melanoma cases were further divided into




Anorectum was the most common anatomic site (n = 39,
30.2%) which was followed by nasal cavity (n = 30, 23.3%),
genitourinary (n = 21, 16.3%), oral cavity (n = 14, 10.9%),
upper gastrointestinal tract (n = 6, 4.7%) and maxillary
sinus (n = 5, 3.9%) in the order of frequency. The age dis-
tributions were similar among different anatomic loca-
tions. In terms of gender, seventy seven patients (59.7%)
were wemen, and fifty two (40.3%) were men, with a
female-to-male ratio of 1.48:1. For those with genitouri-
nary and anorectual melanoma, especially more female
dominant patients were noticed (95.2% and 64.1%,
respectively). Palpable mass was the most common initial
symptom, followed by bleeding, and obstructive symp-
toms. However, patients with upper gastrointestinal (GI)
tract mucosal melanoma presented often with GI symp-
toms, such as dyspepsia, dysphagia, and epigastric dis-
comfort. Of note, 83.3% of melanomas arising from upper
gastrointestinal tract presented with initially dissemi-
nated disease, which was much higher than the rate of
metastatic disease in all cases (16.3%). In all, the most
common site of metastasis was liver (n = 10, 7.8% of all
cases), followed by lung.
Treatment modalities and outcome
Total 87 out of 115 patients (75.6%) received curative
intended surgery, consisted of 62 R0 resected and 25 R1
resected patients. After that, 36 (41.4%) patients received
postoperative adjuvant treatment, 14 were treated withKim et al. BMC Cancer 2010, 10:167
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radiotherapy, 22 had interferon-2bα (n = 14) or dacarba-
zine-based (n = 8) chemotherapy. In terms of relapse pat-
tern, head and neck sites has a tendency to recur locally,
whereas rectal and genitourinary lesions recurred sys-
temically.
For anorectal melanomas, 31 patients underwent wide
excision with regional lymph node dissection and 10
patients with primary resection received postoperative
interferon-2bα (n = 5) or dacarbazine-based chemother-
apy (n = 5) (Table 2). Of the 31 anorectal melanoma
patients with curative resection, 20 (64.5%) patients
developed recurrent disease with 7 local relapse and 13
systemic relapses. The median survival time for anorectal
melanomas was 28.6 months (95% CI, 18.2, 38.9 months).
Table 1: Clinical characteristics of all the 129 patients.




Total Anorectal Genitourinary Upper GI Nasal Oral Maxillary 
sinus
No. 115 39 (30.2) 21 (16.3) 6 (4.7%) 30 (23.3) 14 (10.9) 5 (3.9) 14 (10.9)
Male (%) 45 (39.1) 14 (35.9) 1 (4.8) 3 (50.0) 17 (56.7) 7 (50.0) 3 (60.0) 7 (50.0)
Age (years)
Median 61 62 59 61 63 55 62 64
Range 26-95 31-80 26-95 43-72 39-85 33-74 35-75 28-79
ECOG PS
0-1 113 (98.2) 38(97.4) 20(95.2) 6(100.0) 30(100.0) 14(100.0) 5(100.0) 13(92.9)
≥ 2 2(1.8) 1(2.6) 1(4.8) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 1(7.1)
Presenting 
symptom
Palpable mass 70(60.9) 24(61.5) 16(76.2) 0(0.0) 15(50.0) 13(92.9) 2(40.0) 8(57.1)
Bleeding 24(20.9) 10(25.6) 4(19.0) 1(16.7) 7(23.3) 0(0.0) 2(40.0) 0(0.0)
Obstruction 10(8.7) 1(2.6) 0(0.0) 0(0.0) 7(23.3) 1(7.1) 1(20.0) 0(0.0)
GI symptom 9(7.8) 4(10.3) 0(0.0) 5(83.3) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
Neurologic 
symptom
2(1.7) 0(0.0) 1(4.8) 0(0.0) 1(3.3) 0(0.0) 0(0.0) 6(42.9)
Size (n = 101, mm)
Median (n) 20 34 (n = 33) 18.5(n = 14) 32.5(n = 6) 30 (n = 22) 22(n = 10) 15 (n = 5) 12 (n = 11)
Range 2-135 2-135 4-75 5-60 11-72 5-40 4-35 4-25
Lymph node
N0 78 (67.8) 24(61.5) 14(66.7) 3(50.0) 26(86.7) 7(50.0) 4(80.0) 14(100.0)
N1 20(17.4) 7(17.9) 5(23.8) 0(0.0) 3(10.0) 5(35.7) 0(0.0) 0(0.0)
N2 5(4.3) 2(5.1) 0(0.0) 1(16.7) 1(3.3) 1(7.1) 0(0.0) 0(0.0)
N3 12(10.4) 6(15.4) 2(9.5) 2(33.3) 0(0.0) 1(7.1) 1(20.0) 0(0.0)
Metastatic site
None 95(82.6) 32(82.0) 18(85.7) 1(16.7) 28(93.3) 12(85.7) 4(80.0) 13(92.9)
Liver 10(8.7) 4(10.3) 3(14.3) 2(33.3) 1(3.3) 0(0.0) 0(0.0) 0(0.0)
Lung 7(6.1) 1(2.6) 0(0.0) 3(50.0) 0(0.0) 2(14.3) 1(20.0) 1(7.1)
Peritoneum 1(0.8) 1(2.6) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
Adrenal 1(0.8) 0 0(0.0) 0(0.0) 1(3.3) 0(0.0) 0(0.0) 0(0.0)
Bone 1(0.8) 1(2.6) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
*GI: gastrointestinalKim et al. BMC Cancer 2010, 10:167
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Table 2: Summary of therapeutic and survival data in patients who received curative resection.
Mucosal melanoma (n = 87), N (%) Ocular 
melanoma
N (%)
Total Anorectum Genitourinary Gastrointestinal Nasal Oral Maxillary 
sinus
No. 87 31 17 1 23 11 4 13
R1 resection 25 2(6.5) 5(29.4) 0 12(52.2) 5(45.5) 1(25.0) 5(38.5)
R0 resection 62 29(93.5) 12(70.6) 1(100) 11(47.8) 6(54.5) 3(75.0) 8(61.5)
Adjuvant 
treatment
No 53 20(64.5) 8(47.1) 1(100) 18(78.3) 4(36.4) 2(50.0) 7(53.8)
Chemotherapy 22 10(32.3) 6(35.3) 0 0(0.0) 4(36.4) 0 2(15.4)
IFN 14 5 4 0 0(0.0) 3 0 2
Cytotoxic 8 5 2 0 0(0.0) 1 0 0
Radiotherapy 
only
14 1(3.2) 3(17.6) 0 5(21.7) 3(27.2) 2(50.0) 4(30.8)
Relapse after 
resection
None 36 11(35.5) 7(41.2) 0 12(52.2) 5(45.4) 1(25.0) 6(46.2)
Local relapse 21 7(22.6) 1(5.9) 0 8(34.8) 4(36.4) 1(25.0) 4(30.8)







9 (17.6) 3 2 0 3 1 0 3(42.9)
Radiotherapy 
only
10 (19.6) 3 2 0 2 3 0 1(14.3)
Resection 6 (11.7) 2 1 1 011 0
Current status
No evidence of 
disease
31 (35.6) 12(38.7) 7(41.2) 0 7(30.4) 5(45.5) 0(0.0) 5(38.5)
Alive with 
disease
6 (6.9) 1(3.2) 1(5.9) 0 2(8.7) 1(9.0) 1(25.0) 2(15.3)
Dead of 
disease
50 (57.5) 18(58.1) 9(52.9) 1(100) 14(60.9) 5(45.5) 3(75.0) 6(46.2)
Overall Survival 
(%)
2 years 59.7 61.3 68.4 - 46.9 53.0 75.0 73.3
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For genitourinary melanoma (n = 21), 17 (81.0%) patients
underwent radical cancer surgery and nine patients
received postoperative treatment (interferon-2bα, n = 4;
chemotherapy, n = 2; radiotherapy, n = 3). Median sur-
vival time was 43.9 months which is longer than that for
anorectal melanoma, and approximately half of the cura-
tively resected genitourinary melanoma patients devel-
oped systemic relapses. Melanomas arising from upper
gastrointestinal tract (n = 6) pursued the most aggressive
c l i n i c a l  c o u r s e  w i t h  m e d i a n  s u r v i v a l  t i m e  o f  o n l y  7 . 5
months. Five out of six gastrointestinal melanoma
patients presented with initially metastatic disease. Of 30
nasal melanoma cases, 23 patients underwent radical
cancer surgery with curative intent and 11 patients had
R0 resections. The median survival time for curatively
resected nasal melanoma patients was only 23.4 months
and 14 patients died of the disease.
Survival and prognostic factors for survival
After 64.5 (range 4.3-213.0) months of median follow-up,
an estimated 2 and 5-year OS rates in 129 patients were
50.7% and 25.5%, respectively (Figure 1A). At the time of
analysis, 62.8% (n = 81) of patients were dead. The
median overall survival for all patients was 24.4 months
(95% CI 13.2-35.5). Interestingly, survival rate varied
according to different primary anatomic sites (Figure 1B).
Because of different characteristics of ocular mela-
noma, we further analyzed of prognostic factors for the
curatively resected 115 mucosal melanoma patients. At
univariate analysis, patients with age ≤ 50 years lived lon-
ger than those older than 50 years with statistical signifi-
cance (3 year OS, 70.1% vs 33.3%, respectively; P = .003)
as shown in Table 3. For the resection margin, patients
with R0 resection margin demonstrated significantly pro-
longed survival time compared to those with R1 resection
(median OS; 37.5 vs 16.1 months, respectively, P = 0.001).
Patients with oral and genitourinary tract melanoma
demonstrated slightly better tendency of survival than
the others (median OS; 43.9 vs 26.8 months, P = 0.26). In
addition, patients with positive regional LN stage 0-1
demonstrated slightly poorer survival than patients with
LN 2-3 (median OS 32.9 vs 10.5 months, P = .017). How-
ever, patient's gender, and additional adjuvant therapy
had no statistically significant effect on survival out-
comes. We could not analyze about the tumor thickness
because of incomplete data.
We performed multivariate analysis to evaluate the
independent prognostic factors of survival for 87 mucosal
melanoma patients who had received curative resection
(R0 and R1 resection) as shown in Table 3. Clinical
parameters predicting poor survival outcome that were
included in the multivariate analysis were as follows: age
(> 50 years vs = 50 years), gender (female vs male), pri-
mary site (oral and genitoruinary vs the other mucosal
melanomas), lymph node status (N0-1 vs N2-3), complete
resectability (R0 vs  R1 resection). The entered Cox
regression model was used to delineate independent
prognostic factors. Prognostic factors for survival were
primary site (P = .03; relative risk [RR], 2.4; 95% CI, 1.1,
5.4), complete resectability (P = .001; RR, 2.92; 95% CI,
1.58-6.26), and age (P = .008; RR, 2.88; 95% CI, 1.32-5.39).
The prognostic grouping of the 87 patients was per-
formed according to the following criteria: Group 1 (n =
Figure 1 Survival of all noncutaneous melanoma patients (A) and (B) according to primary sites.Kim et al. BMC Cancer 2010, 10:167
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20), no adverse factor; Group 2 (n = 46), one adverse fac-
tors; and Group 3 (n = 21), two adverse factors. The sur-
vival curves according to the prognostic index are
demonstrated in Figure 2. The prognostic model sepa-
rated patients into three risk groups with different sur-
vival outcomes (P < .001). The 2-year OS rates for Group
1, 2, and 3 were 76.5, 64.4, and 24.2%, respectively (Table
4). Group 3 patients had seven folds (HR 7.29, 95% CI
2.64-21.11) increased risk of death compared to Group 1.
Ocular melanoma
For 14 ocular melanoma, 11 were choroidal melanoma,
and 3 were conjunctival melanoma patients. Age and gen-
der distribution was similar with other mucosal mela-
noma patients. Almost all the patients (92.9%) presented
without distant metastasis, and only 1 of 14 cases pre-
sented with metastatic disease to lung (for uveal mela-
noma patient). In terms of treatment, all ocular
melanoma patients except one underwent resection with
curative intent (8 R0 resection and 5 R1 resection). Sur-
vival outcome was much better than mucosal melanoma,
which demonstrated 73.3% of 2 year OS and 51.2 months
of median OS.
Discussion
To provide a more complete clinical picture of this
uncommon disease entity and ultimately deduce the risk-
adapted therapeutic strategies, we analyzed the largest
series of noncutaneous melanomas in terms of clinical
features and prognosis. In this study, we depicted distinc-
tive clinical features of the rare disease entity and catego-
rized heterogeneous subsets of noncutaneous melanoma
into two groups: ocular and nonocular mucosal mela-
noma. Moreover, systemic analyses of prognostic factors
reflecting poor survival have not been reported in noncu-
taneous melanoma patients. Hence, we attempted to
devise a prognostic model incorporating readily available
clinical variables which may assist clinicians for risk strat-
ification.
In this study, the median overall survival for all patients
and mucosal melanoma patients were 24.4 months (95%
CI 13.2-35.5) and 34.6 months (95% CI 24.5-44.7), which
is in accordance with previous studies[18,19]. Based on
those findings, we analyzed significant prognostic factors
of OS for mucosal melanoma patients who had received
curative resection. The significant poor prognostic fac-
tors were microscopic residual disease (P = .001; RR, 2.93;
95% CI 1.58-6.26), and age > 50 years (P = .008; RR, 2.88;
95% CI, 132-5.39) (Table 3). These findings are very con-
sistent with previous study for mucosal melanoma [15].
Figure 2 Survival according risk group as defined by prognostic 
models.
Table 3: Prognostic Factors of Survival for 87 mucosal melanoma patients who had received curative resection (R0 and R1 
resection).
Univariate Multivariate analyses
Parameters P value Relative Risk (exp. B) P value
Age (≤ 50 years vs > 50 years) 0.003 2.88 (1.32-5.39) 0.008
Sex (female vs male) 0.43 1.21 (0.66-2.23) 0.54
Adjuvant treatment (done vs 
not done)
0.76 1.02 (0.54-1.94) 0.94
Primary site
(oral and genitourinary vs 
others)
0.26 1.63 (0.81-3.29) 0.17
Lymph nodes (N0-1 vs N2-3) 0.17 1.91 (0.51-7.19) 0.34
Complete resectability (RO vs 
R1)
0.001 2.93 (1.58-6.26) 0.001Kim et al. BMC Cancer 2010, 10:167
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In the multivariate analysis, age greater than 60 years was
one of the poor prognostic factors for survival. Contrary
to cutaneous melanoma, achieving extensive resection is
very difficult due to anatomical location or cosmetic con-
cerns, and performing radical lymphadenectomy is much
more challenging. Based on those results, more attention
is required for achieving R0 resection for mucosal mela-
noma patients. In addition, even after the curative
intended resection, patients with microscopically residual
resection should be offered of more aggressive therapeu-
tic strategy such as postoperative chemotherapy ± radio-
therapy. Due to the inherent bias for retrospective study
in nature and the limited sample size, this result should
be prospectively validated before clinical application.
Importantly, the survival outcome seems to differ
according to the primary site of nonocular mucosal mela-
noma. For instance, 5 of 6 gastrointestinal melanomas
presented with disseminated disease and pursued a rap-
idly deteriorating natural course with median survival
time of 7.5 months. There are several anecdotal case
reports on primary gastric or esophageal melanoma
which reported poor survival following resection in
accordance with our observation [20-22]. In contrast,
ocular melanomas exceptionally pursued a favorable clin-
ical course with median survival of 51.2 months. Most of
the ocular melanoma patients (13 of 14, 93%) presented
with localized disease of whom eight achieved R0 resec-
tion. One of the plausible explanations for such signifi-
cant difference in prognosis would owe to the anatomic
location. For instance, ocular melanoma may be more
noticeable and symptomatic than gastric melanoma;
thus, over 90% of the ocular melanoma patients are diag-
nosed at localized stage. As shown in Figure 1B, genito-
urinary, anorectal and head and neck melanomas
demonstrated relatively similar survival pattern.
In all, of the 100 noncutaneous melanoma patients who
underwent surgical resection with curative intent, 70
patients achieved complete R0 resection and 58 devel-
oped recurrence (43% local relapse, 57% systemic
relapse). Of the 51 recurred patients, only 6 patients
underwent re-resection and half of the patients did not
receive palliative treatment. Considering the high rate of
systemic relapse following curative resection observed in
our study along with previous reports [14,23], an effective
postoperative systemic treatment is urgently needed. The
role of adjuvant treatment in mucosal melanoma has not
been extensively studied compared to cutaneous mela-
noma probably owing to the rarity of disease. Several
studies on adjuvant treatment using chemotherapeutic or
immunotherapeutic agents, the results have been disap-
pointing[4,24-27]. In line with these studies, our retro-
spective analysis on 100 noncutaneous melanoma
patients with surgical resection showed no significant dif-
ference in survival associated with adjuvant chemother-
apy (median survival; 45.3 months vs  34.5 months,
adjuvant therapy vs observation, respectively, P = .085). In
subgroup analysis, however, there was a trend toward
better survival in anorectal and genitourinary mucosal
melanoma patients who received postoperative chemo-
therapy (median OS 45.3 months vs 26.1 months, respec-
tively,  P  = .20). Therefore, the role of adjuvant
chemotherapy or immunotherapy should be actively
sought in noncutaneous melanoma in the context of clin-
ical trial.
A potential breakthrough in the management of
mucosal melanoma has been recently suggested by the
observation of relatively high incidence of KIT mutations
in mucosal melanomas [28-30]. Excitingly, a major
response has been reported following imatinib treatment
in primary anal melanoma patient harboring a seven-
codon duplication in exon 11 of KIT [31]. Other reports
also support the use of specific kinase inhibitors such as
imatinib or dasatinib in melanoma patients with activat-
ing KIT mutation [30,32]. Given the high incidence of
KIT mutations in mucosal melanoma, we plan to conduct
a phase II clinical trial with KIT targeting small molecule
in this subset of patients.
Conclusion
This is the first study to comprehensively review and
describe the clinical features and prognosis of noncutane-
ous melanoma. Nonocular mucosal melanoma pursued
an aggressive clinical course and high rate of systemic
relapse following curative resection and thus, more
aggressive postoperative treatment should be considered
for the patients with poor risk factors. Moreover, further
validation and postoperative study with different strategy
is warranted in the future.
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